Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy

Akçay G., Kanar H. S., Kivrak U., Uslubas I., Arsan A. K.

BMC Ophthalmology, cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1186/s12886-026-04917-3
  • Dergi Adı: BMC Ophthalmology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: Acute central serous chorioretinopathy, Optic coherence tomography, Subthreshold micropulse laser, Yellow wavelength laser
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Purpose: To assess the subthreshold micropulse laser (SML) treatment in patients with acute central serous chorioretinopathy (CSC). Materials and methods: This retrospective study included 46 eyes from 46 patients with acute CSC. Twenty-five patients were treated with SML, while 21 were observed without intervention. Outcomes evaluated included best corrected visual acuity (BCVA), outer nuclear layer thickness (ONLT), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) height. SML was applied using a 577 nm yellow wavelength laser. Results: In the SML group, BCVA improved significantly from 0.33 ± 0.13 LogMAR at baseline to 0.07 ± 0.05 LogMAR at 6 months (p < 0.001). The observation group showed improvement from 0.29 ± 0.13 LogMAR to 0.14 ± 0.16 LogMAR (p = 0.011). SFCT decreased significantly in the SML group (460.36 ± 67.91 μm at baseline to 407.44 ± 60.18 μm at 6 months, p = 0.013), with no significant change in the observation group. The SML group also showed a significant increase in ONLT (p < 0.001), and complete SRF resorption was achieved in all patients, compared to 23.8% in the observation group. Conclusion: SML treatment is a safe and effective option for managing acute CSC. Trial registration number: 2024/010.99/2/21-27.03.2024, retrospective design.